These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20945090)

  • 21. A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer.
    Hamelinck VC; Bastiaannet E; Pieterse AH; de Glas NA; Portielje JE; Merkus JW; den Hoed ID; van de Velde CJ; Liefers GJ; Stiggelbout AM
    Clin Breast Cancer; 2016 Oct; 16(5):379-388. PubMed ID: 27212474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.
    Duric VM; Butow PN; Sharpe L; Boyle F; Beith J; Wilcken NR; Heritier S; Coates AS; John Simes R; Stockler MR
    Psychooncology; 2007 Jan; 16(1):48-59. PubMed ID: 16856128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant therapy for all patients with breast cancer?
    Lippman ME; Hayes DF
    J Natl Cancer Inst; 2001 Jan; 93(2):80-2. PubMed ID: 11208870
    [No Abstract]   [Full Text] [Related]  

  • 25. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making.
    Engelhardt EG; Pieterse AH; van der Hout A; de Haes HJ; Kroep JR; Quarles van Ufford-Mannesse P; Portielje JE; Smets EM; Stiggelbout AM
    Eur J Cancer; 2016 Oct; 66():55-66. PubMed ID: 27525573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
    Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
    Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?
    Simes RJ; Coates AS
    J Natl Cancer Inst Monogr; 2001; (30):146-52. PubMed ID: 11773309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour.
    Cahir C; Dombrowski SU; Kelly CM; Kennedy MJ; Bennett K; Sharp L
    Support Care Cancer; 2015 Nov; 23(11):3115-30. PubMed ID: 25744290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results].
    Kahlert S; von Koch F; Ditsch N; Untch M
    Gynakol Geburtshilfliche Rundsch; 2004 Apr; 44(2):102-12. PubMed ID: 15073439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring patient experiences of neo-adjuvant chemotherapy for breast cancer.
    Beaver K; Williamson S; Briggs J
    Eur J Oncol Nurs; 2016 Feb; 20():77-86. PubMed ID: 26078034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach.
    Lin FP; Pokorny A; Teng C; Dear R; Epstein RJ
    BMC Cancer; 2016 Dec; 16(1):929. PubMed ID: 27905893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.
    Whelan T; Sawka C; Levine M; Gafni A; Reyno L; Willan A; Julian J; Dent S; Abu-Zahra H; Chouinard E; Tozer R; Pritchard K; Bodendorfer I
    J Natl Cancer Inst; 2003 Apr; 95(8):581-7. PubMed ID: 12697850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.